Intra-Cellular Therapies ( (ITCI) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Intra-Cellular Therapies’ stock has gained momentum following a favorable patent litigation settlement with Sandoz regarding its product, Caplyta. This agreement potentially extends Caplyta’s market exclusivity until July 1, 2040, boosting investor confidence in its revenue durability. Analysts, including those from JPMorgan and RBC Capital, see this as a positive development, leading to expected upward revisions in consensus price targets. However, RBC Capital has slightly lowered its price target due to broader market factors.
More about Intra-Cellular Therapies
YTD Price Performance: -1.99%
Average Trading Volume: 561,789
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $8.75B
For further insights into ITCI stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.